NMRA NEUMORA THERAPEUTICS INC. revenue, earnings and financials
For the quarter ended June 30, 2026, NEUMORA THERAPEUTICS INC. reported revenue of n/a, net income of −$43.1M and diluted EPS of −$0.23; for the fiscal year ended December 2025 revenue was n/a.
NMRA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$241M, net income $237M (margin n/a), EPS −$1.45
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$263M, net income $244M (margin n/a), EPS −$1.53
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$252M, net income −$236M (margin n/a), EPS −$3.63
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$136M, net income −$131M (margin n/a), EPS −$4.81
NMRA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$43.1M, EPS −$0.23
- Quarter ended Mar 31, 2026: revenue n/a, net income −$53.5M, EPS −$0.30
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income $414M, EPS −$0.35
- Quarter ended Sep 30, 2025: revenue n/a, net income −$56.8M, EPS −$0.35
- Quarter ended Jun 30, 2025: revenue n/a, net income −$52.7M, EPS −$0.33
- Quarter ended Mar 31, 2025: revenue n/a, net income −$68.0M, EPS −$0.42
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income $429M, EPS −$0.37
- Quarter ended Sep 30, 2024: revenue n/a, net income −$72.5M, EPS −$0.45
- Quarter ended Jun 30, 2024: revenue n/a, net income −$58.7M, EPS −$0.37
- Quarter ended Mar 31, 2024: revenue n/a, net income −$53.7M, EPS −$0.34
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$109M, EPS $0.01
- Quarter ended Sep 30, 2023: revenue n/a, net income −$53.0M, EPS −$1.14
- Quarter ended Jun 30, 2023: revenue n/a, net income −$38.5M, EPS −$1.28
- Quarter ended Mar 31, 2023: revenue n/a, net income −$35.6M, EPS −$1.22
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$28.1M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$29.3M, EPS −$1.06
- Quarter ended Jun 30, 2022: revenue n/a, net income −$30.4M, EPS n/a
- Quarter ended Mar 31, 2022: revenue n/a, net income −$43.0M, EPS n/a
NMRA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$206M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$183M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$163M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$115M, share buybacks n/a
NMRA balance sheet
- Jun 30, 2026: cash $117M, total assets $125M, total liabilities $80.7M, shareholders' equity $44.5M, long-term debt $52.9M
- Mar 31, 2026: cash $147M, total assets $154M, total liabilities $83.2M, shareholders' equity $70.7M, long-term debt $53.0M
- Dec 31, 2025: cash $183M, total assets $191M, total liabilities $87.2M, shareholders' equity $104M, long-term debt $54.5M
- Sep 30, 2025: cash $129M, total assets $178M, total liabilities $45.7M, shareholders' equity $132M, long-term debt $19.6M
- Jun 30, 2025: cash $125M, total assets $224M, total liabilities $40.9M, shareholders' equity $183M, long-term debt $19.5M
- Mar 31, 2025: cash $127M, total assets $257M, total liabilities $28.4M, shareholders' equity $228M
- Dec 31, 2024: cash $142M, total assets $317M, total liabilities $29.9M, shareholders' equity $287M, long-term debt $0
- Sep 30, 2024: cash $276M, total assets $353M, total liabilities $31.8M, shareholders' equity $321M
Is NMRA profitable?
Yes. NEUMORA THERAPEUTICS INC. earned $261M over the last four quarters.
What is NMRA's EPS?
Diluted earnings per share over the last four quarters were −$1.23; −$0.23 in the latest quarter.